Alimera Sciences, Inc (ALIM)

Etorro trading 970x250
Alimera Sciences, Inc (ALIM) Logo

About Alimera Sciences, Inc

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia. Address: 6120 Windward Parkway, Alpharetta, GA, United States, 30005

Alimera Sciences, Inc News and around…

Latest news about Alimera Sciences, Inc (ALIM) common stock and company :

Recent 24-Month Real-World PALADIN Data Demonstrate the Ability of ILUVIEN® to Significantly Reduce Treatment Burden in Patients with Diabetic Macular Edema
13 Oct, 2021 Yahoo! Finance

PALADIN Study Data Presented at the American Society of Retina Specialists Shows That Post-ILUVIEN, the Percentage of Eyes Receiving One Yearly Treatment or Less Increased 3.2-Fold Compared to Pre-ILUVIEN ATLANTA, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and to maintain better vision longer, announces a data presentation

12 Health Care Stocks Moving In Monday's Intraday Session
04 Oct, 2021 FinancialContent

Gainers Progenity (NASDAQ:PROG) stock moved upwards by 18.43% to $2.12 during Monday's regular session. Trading ...

Alimera Sciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference
02 Sep, 2021 FinancialContent
Alimera Sciences Announces National Pricing and Reimbursement Granted for ILUVIEN® for DME in Belgium
24 Aug, 2021 FinancialContent
60 Biggest Movers From Yesterday
17 Aug, 2021 FinancialContent

Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares jumped 33.7% to close at $3.37 on Monday after the company announced plan to ...

Alimera Sciences, inc (ALIM) Q2 2021 Earnings Call Transcript
13 Aug, 2021 FinancialContent

ALIM earnings call for the period ending June 30, 2021.

Recap: Alimera Sciences Q2 Earnings
13 Aug, 2021 FinancialContent

Shares of Alimera Sciences (NASDAQ:ALIM) moved higher by 5.3% in pre-market trading after the company reported Q2 results. Quarterly ...

Alimera Sciences (ALIM) Q2 Earnings and Revenues Miss Estimates
13 Aug, 2021 Yahoo! Finance

Alimera Sciences (ALIM) delivered earnings and revenue surprises of -39.20% and -6.85%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Alimera Sciences Announces Second Quarter 2021 Financial Results
13 Aug, 2021 FinancialContent
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
13 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Earnings Scheduled For August 13, 2021
13 Aug, 2021 FinancialContent

Companies Reporting Before The Bell • Jaguar Health (NASDAQ:JAGX) is expected to report quarterly loss at $0.03 per ...

How Does Alimera Sciences's Debt Look?
11 Aug, 2021 FinancialContent

Over the past three months, shares of Alimera Sciences (NASDAQ:ALIM) fell by 3.92%. Before we understand the importance of ...

Alimera Sciences to Report Second Quarter 2021 Financial Results on Friday, August 13, 2021, and Provide Corporate Update
10 Aug, 2021 FinancialContent

Conference Call to be held Friday, August 13, 2021, at 9:00 am Eastern Time

Alimera Sciences and Tanner Pharma Group Initiate Global Named Patient Program for ILUVIEN®
09 Aug, 2021 Yahoo! Finance

ATLANTA, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences Europe Limited (“Alimera”), a wholly owned subsidiary of Alimera Sciences, Inc., and Tanner Pharma UK Limited (“Tanner”) announced today the initiation of a Named Patient Program for ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg globally for the treatment of diabetic macular edema (DME) and in Europe and the Middle East, for the treatment of non-infectious posterior uveitis (NIU-PS). The agreement names Tanner as the ex

Alimera Sciences (ALIM) Earnings Expected to Grow: Should You Buy?
28 Jul, 2021 Yahoo! Finance

Alimera Sciences (ALIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Investors Who Bought Alimera Sciences (NASDAQ:ALIM) Shares A Year Ago Are Now Up 104%
05 Jun, 2021 Yahoo! Finance

When you buy shares in a company, there is always a risk that the price drops to zero. But if you pick the right...

35 of the Best Ideas Companies to Present at the Summer Solstice - Best Ideas from the Buy-Side Virtual Investor Conference on June 1-4, 2021
27 May, 2021 Yahoo! Finance

RALEIGH, NC / ACCESSWIRE / May 27, 2021 / The Summer Solstice - Best Ideas from the Buy-Side will take place on June 1-4, 2021, where 35 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience.The Summer Solstice - Best Ideas from the Buy Side: VIRTUAL begins on Tuesday, June 1, 2021, with company presentations beginning at 9am Eastern Time.

Alimera Sciences, Inc. to Present at the Summer Solstice – Best Ideas from the Buy Side Conference on June 2, 2021
27 May, 2021 FinancialContent
Alimera Sciences Appoints David Dyer, M.D. as Chief Retina Specialist
17 May, 2021 FinancialContent
Alimera Sciences Inc (ALIM) Q1 2021 Earnings Call Transcript
29 Apr, 2021 FinancialContent

ALIM earnings call for the period ending March 31, 2021.

The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx
29 Apr, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Alimera Sciences, Inc. to Host Earnings Call
29 Apr, 2021 Yahoo! Finance

NEW YORK, NY / ACCESSWIRE / April 29, 2021 / Alimera Sciences, Inc. (NASDAQ:ALIM) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on April 29, 2021 at 9:00 AM Eastern Time.

Alimera Sciences (ALIM) Reports Q1 Loss, Lags Revenue Estimates
28 Apr, 2021 Yahoo! Finance

Alimera Sciences (ALIM) delivered earnings and revenue surprises of -26.00% and -3.33%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Recap: Alimera Sciences Q1 Earnings
28 Apr, 2021 FinancialContent

Shares of Alimera Sciences (NASDAQ:ALIM) were flat in after-market trading after the company reported Q1 results. Quarterly ...

Alimera Sciences Announces First Quarter 2021 Financial Results
28 Apr, 2021 FinancialContent
The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping
28 Apr, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Alimera Science's Innovative Treatment for Diabetic Macular Edema Vision Loss Lasts for up to 3 Years
26 Apr, 2021 Yahoo! Finance

Intravitreal Implant Provides a Daily Microdose Release to Reduce Disease Recurrence Amid required stay-at-home orders, many have paused or canceled doctor’s appointments over the past 12 months. Recent studies show some of the troubling effects of patients missing out on treatments for vision loss. Alimera Sciences believes it has a solution. A Daily Microdose Recently, the Cleveland Clinic published a paper, “The Effect of Delay in Care Among Patients Requiring Intravitreal Injections,” regarding the results of patients missing their prescribed vision loss treatments due to the COVID pandemic. This 1,041-patient retrospective analysis examined the effect of a delay in care on the visual acuity of patients requiring intravitreal injections. The authors looked at patients with retina disease who had received an intravitreal injection in the 12-week period prior to March 14, 2020 (start of the lockdowns). Patients in the study were divided into 3 groups: those that completed their scheduled visit during the time period from March 14 to May 4, 2020; those that canceled their scheduled visit during that period; and no-shows. Upon returning to the office after those 7 weeks, patients who either canceled or were no-shows experienced statistically significant vision loss compared to the patients who completed their scheduled visits during the study period. The studies’ authors concluded that patients with DME and/or proliferative diabetic retinopathy and retinal vein occlusion are most vulnerable to vision loss with even short lapses in care. A second study conducted by Dr. Ashkanazy and others from Bascom Palmer Eye Institute drew a similar conclusion. But with such a dangerous pandemic underway, such regular care ceased to become an option using intravitreal injections, posing the larger problem of how to more effectively mitigate vision loss regardless of the presence of a global pandemic. An Injection Every 3 Years Enter Alimera Sciences, which developed ILUVIEN®, an implantable treatment for diabetic macular edema, thereby requiring far fewer treatments over a larger span of time. The sustained-release intravitreal implant is injected into the back of the eye and lasts up to 3 years. It is designed to release a daily submicrogram level of fluocinolone acetonide (a corticosteroid) for 36 months to reduce the recurrence of disease and the number of treatments required, enabling patients to maintain vision longer with fewer injections. ILUVIEN is approved in the U.S., Canada, Kuwait, Lebanon and the United Arab Emirates to treat diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. It is approved for DME in several European countries under a different indication. In March 2019, ILUVIEN received approval in 17 European countries under the Mutual Recognition Procedure for prevention of relapse in recurrent noninfectious uveitis affecting the posterior segment of the eye. Why Invest? With over 500,000 DME patients in the U.S. and over 900,000 in the European Union, Alimera Sciences believes this to be a $2 billion global market opportunity. Currently, typical injections to treat the disease last only 1-3 months compared with Alimera’s 3-year-long ILUVIEN implant. With this model of consistent delivery, sustained effects and fewer injections, the company is confident in the success of its product and believes investors should be, too. Alimera’s goal is to be synonymous with good retinal health. The company has a passion for protecting the retina to preserve vision and strives to work hard, collaborate and commercialize products that will help patients maintain their vision longer. Its mission is to be invaluable to patients, physicians and partners concerned with retinal health. Find out more at https://alimerasciences.com/. See more from BenzingaClick here for options trades from BenzingaInvestment Arm of World's Second-Largest Reinsurer Swoops In On Nio, Tesla Stock In Q1Amazon Invests In 9 Renewable Energy Projects In 5 Countries© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx
24 Apr, 2021 FinancialContent

Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & ...

Alimera Sciences to Report First Quarter 2021 Financial Results on Wednesday, April 28, 2021 and Provide Corporate Update
22 Apr, 2021 FinancialContent

Conference Call to be held Thursday, April 29, 2021 at 9:00am Eastern Time

Week In Review: Sinopharm Transfers $4.6 Billion In Assets, Including Two COVID-19 Vaccines
17 Apr, 2021 FinancialContent

Sinopharm Group will transfer six of its vaccine companies to Beijing Tiantan Biological Products. Two of the transferring companies have approved COVID-19 vaccines, and Sinopharma said a public listing will facilitate additional sources of funding.

Alimera Sciences, Inc (ALIM) is a NASDAQ Common Stock listed in , ,

970x250